Cello acquires Advantage Healthcare

Press Release: Cello Group plc (AIM: CLL; “Cello”, the “Group” or the “Company), the healthcare and strategic marketing group, is pleased to announce the acquisition of the assets of Advantage Healthcare Inc (“Advantage Healthcare”). The proposed initial consideration for the Acquisition is US$1.5 million, which is payable in cash. Further cash consideration will be paid to the vendors on a dollar for dollar basis to the extent that the acquired net current assets of Advantage Healthcare are over US$0.5 million at the date of completion. In addition, deferred consideration of up to US$3.00 million will be payable in a mix of cash and shares, dependent on financial performance over the period from 1 July 2017 to 30 June 2021. This deferred consideration will be paid in a minimum of 75% cash, with the balance in new ordinary shares

read more

Cello acquires Defined Health

Press Release: Cello Group plc (AIM: CLL; “Cello”, the “Group” or the “Company), the healthcare focused strategic marketing group, is pleased to announce that it has raised £15.0 million (before expenses) by way of a placing of 15,463,919 new ordinary shares of 10 pence each (the “Placing Shares”) at a price of £0.97 per ordinary share (the “Placing”). The Placing, which was oversubscribed, has received strong support from both new and existing institutional shareholder. The Placing proceeds will in part be used to finance the acquisition of the assets of Defined Healthcare Research, Inc. and Cancer Progress, LLC (“Defined Health”), a business delivering scientific strategic advisory services to a wide range of US, European and global biotech and healthcare clients (the “Acquisition”). The proposed initial consideration for the Acquisition is US$5.75 million

read more

Cello’s Interims 2013 announced

In announcing Cello’s Interim results 2013, Mark Scott, Chief Executive, commented: “The refocusing of the Group last year into Cello Health and Cello Consumer has begun to demonstrate its potential to deliver strong performance…..”

read more

Cello's Interims 2013 announced

In announcing Cello’s Interim results 2013, Mark Scott, Chief Executive, commented: “The refocusing of the Group last year into Cello Health and Cello Consumer has begun to demonstrate its potential to deliver strong performance…..”

read more

Cello Health acquires Mash Health inc

Cello Group plc, the insight and strategic marketing group, announces the acquisition of Mash Health Limited and Mash Health, Inc. Initial consideration is approximately £0.6 million, with further performance related consideration of up to a maximum of £0.9 million.

read more